Ernexa Therapeutics Inc.SEC Filings
|
|
All SEC filings by Ernexa Therapeutics Inc. (ERNA) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| ARS | Annual report to shareholders | May 11, 2026 | ||
| 10-Q | Quarterly report | View Diff | May 11, 2026 | |
| 10-K | Annual report | View Diff | Mar 13, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 7, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 13, 2025 | |
| 10-Q | Quarterly report | View Diff | May 7, 2025 | |
| ARS | Annual report to shareholders | Apr 14, 2025 | ||
| 10-K | Annual report | View Diff | Mar 12, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 12, 2024 |
Events
| 8-K | Regulation Fd Disclosure | Jul 2, 2026 | ||
| 8-K | Current report | Jul 2, 2026 | ||
| 8-K | Current report | Jun 26, 2026 | ||
| 8-K | Amendments to Articles of Incorporation or Bylaws | May 4, 2026 | ||
| 8-K | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard | Mar 20, 2026 | ||
| 8-K | Regulation Fd Disclosure | Feb 26, 2026 | ||
| 8-K | Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering | Feb 11, 2026 | ||
| 8-K | Regulation Fd Disclosure | Dec 11, 2025 | ||
| 8-K | Changes in Registrant'S Certifying Accountant | Jul 7, 2025 | ||
| 8-K | Amendments to Articles of Incorporation or Bylaws | Jun 12, 2025 |
Registrations and Prospectuses
| S-3/A | Shelf registration | View Diff | Mar 24, 2026 | |
| S-3 | Shelf registration | View Diff | Mar 13, 2026 | |
| 424B5 | Prospectus supplement for primary offering | Feb 10, 2026 | ||
| 8-A12B | Registration of securities on exchange | Feb 5, 2026 | ||
| S-1/A | IPO registration | View Diff | Feb 5, 2026 | |
| S-1/A | IPO registration | View Diff | Feb 3, 2026 | |
| S-1 | IPO registration | View Diff | Feb 2, 2026 | |
| DRS | Draft registration statement | Oct 23, 2025 | ||
| 424B3 | Prospectus supplement | Jun 18, 2025 | ||
| S-8 | Registration of securities for employees | Jun 11, 2025 |
Proxies
| DEFA14A | Additional proxy soliciting materials | May 11, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | May 11, 2026 | |
| DEF 14C | Information statement | Apr 13, 2026 | ||
| PRE 14C | Preliminary information | Apr 1, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 14, 2025 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 3, 2025 | |
| DEF 14A | Definitive proxy | View Diff | Oct 7, 2024 | |
| PRE 14A | Preliminary proxy | View Diff | Sep 27, 2024 | |
| DEFA14A | Additional proxy soliciting materials | May 9, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | May 5, 2023 |
Other
| EFFECT | Notice of effectiveness | Mar 31, 2026 | ||
| CORRESP | Correspondence with SEC | Mar 26, 2026 | ||
| UPLOAD | Letter from SEC | Mar 20, 2026 | ||
| EFFECT | Notice of effectiveness | Feb 6, 2026 | ||
| CERT | Certification of approval for exchange listing | Feb 5, 2026 | ||
| EFFECT | Notice of effectiveness | Jun 20, 2025 | ||
| UPLOAD | Letter from SEC | Jun 16, 2025 | ||
| CORRESP | Correspondence with SEC | Jun 16, 2025 | ||
| EFFECT | Notice of effectiveness | Apr 30, 2025 | ||
| CORRESP | Correspondence with SEC | Apr 25, 2025 |
Ownership
| 4 | Bristol James Arthur | Sep 1, 2026 | ||
| 4 | Cicala Peter | Sep 1, 2026 | ||
| 4 | Polinsky David | Sep 1, 2026 | ||
| 4 | Wexler William A. | Sep 1, 2026 | ||
| 4 | Ratner Elena | Sep 1, 2026 | ||
| 4 | Luther Sanjeev | Sep 1, 2026 | ||
| 3 | Polinsky David | Aug 27, 2026 | ||
| SC 13G/A | Beneficial ownership report | May 20, 2026 | ||
| SC 13G/A | Beneficial ownership report | May 15, 2026 | ||
| SC 13G/A | Beneficial ownership report | May 15, 2026 |